BIOMAT Database Logo BIOMAT Database Logo

Drugs in the aetiology of agranulocytosis and aplastic anaemia. 1996

D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Slone Epidemiology Unit, Boston University School of Medicine, MA 02146, USA.

Agranulocytosis and aplastic anaemia are rare but serious conditions known to be caused by numerous drugs. Most of what is known or suspected about the aetiology is based on case reports, with only a few formal epidemiological studies that provide quantitative estimates of risk. Updated results have been obtained from a combined analysis of data from 3 case-control studies that used similar methods: the International Agranulocytosis and Aplastic Anemia Study (IAAAS), conducted in Israel and Europe; a study conducted in the northeast US; and a study conducted in Thailand. Totals of 362 cases of agranulocytosis, 454 cases of aplastic anaemia and 6458 controls were included in the analyses. The IAAAS and Thai study were population-based, providing estimates of the incidence of the 2 dyscrasias. The overall annual incidence of agranulocytosis in the ambulatory population was 3.4/10(6) in the IAAAS and 0.8/10(6) in Thailand; by contrast the incidence of aplastic anaemia was 2.0/10(6) in the IAAAS and 4.1/10(6) in Thailand. A total of 21 compounds were significantly associated with an increased risk of agranulocytosis in the IAAAS and US studies. Excess risks ranged from 0.06 to 13 cases/10(6) users/wk; the most strongly associated drugs were procainamide, anti-thyroid drugs and sulphasalazine. An association with drugs that had previously been suspected was also seen in Thailand. The overall aetiologic fractions of agranulocytosis due to drug use were 62% in the IAAAS, 72% in the US and 70% in Thailand. Eleven drugs were significantly associated with an increased risk of aplastic anaemia, with excess risks ranging from 1.4 to 60 cases/10(6) users in a 5-month period. The most strongly associated drugs were penicillamine, gold and carbamazepine. Aetiologic fractions were 27% in the IAAAS, 17% in the US and 2% in Thailand, which paralleled the prevalence of use of associated drugs in the 3 populations. The present results confirm that agranulocytosis is largely a drug-induced disease, with similar proportions accounted for in 3 disparate geographic regions. By contrast, although many of the expected associations were observed for aplastic anaemia, most of the aetiology is not explained by drugs. For all associated drugs, the excess risks are sufficiently low that blood dyscrasias should not figure prominently in the balancing of risks and benefits.

UI MeSH Term Description Entries
D007557 Israel A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon. The capital is Jerusalem.
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D000741 Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. Anemia, Hypoplastic,Aplastic Anaemia,Aplastic Anemia,Anaemia, Aplastic,Aplastic Anaemias,Aplastic Anemias,Hypoplastic Anemia,Hypoplastic Anemias
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. International Agranulocytosis and Aplastic Anaemia Study.
July 1988, BMJ (Clinical research ed.),
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Analgesics, agranulocytosis, and aplastic anaemia.
January 1987, Lancet (London, England),
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Aplastic anaemia. I. Incidence and aetiology.
October 1972, Acta medica Scandinavica,
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Aplastic anaemia--aetiology and clinical features.
January 1989, Bailliere's clinical haematology,
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Aplastic anaemia and agranulocytosis following chlorpromazine therapy.
January 1960, The Medical journal of Australia,
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
[Drugs, agranulocytosis and aplastic anemia].
November 1986, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Prostaglandins and drug induced agranulocytosis, aplastic anaemia and leukemia.
March 1979, Prostaglandins and medicine,
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Drug-induced aplastic anaemia and agranulocytosis. Incidence and mechanisms.
January 1986, Drugs,
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
[Agranulocytosis and aplastic anemia induced by drugs].
April 1987, Medicina clinica,
D W Kaufman, and J P Kelly, and J M Jurgelon, and T Anderson, and S Issaragrisil, and B E Wiholm, and N S Young, and P Leaverton, and M Levy, and S Shapiro
Analgesics, agranulocytosis, and aplastic anaemia: a major case-control study.
October 1986, Lancet (London, England),
Copied contents to your clipboard!